latest news releases from the newsroom
LGP Allgon to supply mobile coverage for the Olympics in Athens 2004
STOCKHOLM, Sweden, March 16, 2004 (PRIMEZONE) -- LGP Allgon, the global supplier of infrastructure solutions for mobile communications networks, has been appointed coverage solution provider of the Olympic Games in Athens 2004. The coverage solution is provided to Vodafone through LGP Allgon's distributor in Greece, Plural.
Invitation to Annual General Meeting of Trelleborg AB
STOCKHOLM, Sweden, March 16, 2004 (PRIMEZONE) -- The shareholders of Trelleborg AB (publ) are hereby invited to attend the Annual General Meeting of the Company on Thursday, April 22, 2004, at 3 p.m. in the Soderslattshallen, Klorupsvagen 48, Trelleborg, Sweden.
ML Laboratories Renews PER.C6(TM) License Agreement with Crucell
LEIDEN, The Netherlands, March 16, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that UK-based ML Laboratories has decided to renew its PER.C6(tm) technology license agreement. Under the renewed agreement, the parties have negotiated research and commercial terms for gene therapy products developed and manufactured on PER.C6(tm) technology. Further details were not disclosed.
Biotech Stock Review
Top 10 Performing Biotech Stocks According to Biotech Stock Review
BEVERLY HILLS, Calif., March 15, 2004 (PRIMEZONE) -- The Biotech Stock Review issued the "Top 10 Performing Biotech Stocks" list, for the week ending 3/12/2004. For the prior three month period, the Top 10 Performing Biotech Stocks gained an average of 127%. During the same time-period the average Biotech stock gained 11%, vs. a gain of 2% for the NASDAQ 100.
Medifast Announces Record Revenue and Pre-Tax Profits for 4th Quarter and 2003 Year-End
OWINGS MILLS, Md., March 15, 2004 (PRIMEZONE) -- Medifast, Inc. (AMEX:MED) reported today record fourth quarter and fiscal 2003 full-year revenues and pre-tax earnings for the period and year ended December 31, 2003. The Company reported fourth quarter revenues of $5.84 million, a 30% increase versus the same period in the year-earlier period. Medifast reported pre-tax Income from Operations of $511,000, or $0.06 per share ($0.05 per share on a fully diluted basis), a 190% increase versus $176,000, or $0.03 per share ($0.02 per share on a fully diluted basis) for the fourth quarter of 2002.